Future use of c-jun n-terminal kinase inhibitors
Keywords:JNK, CP-1347, SP600125, AS601245, CC-930, curcumin, catechin, epigallocatechin-3-gallate, resveratrol
AbstractJNK kinase is a group of stress-activated kinases that are involved in apoptosis, growth, development and differentiation of cells. JNK kinase activation is observed in the development of inflammatory processes, neurodegenerative disorders, insulin resistance, diabetes, cancer. Therefore, the search for new inhibitors of kinases JNK is an important and urgent problem. In this article novel synthetic
inhibitors and inhibitors of plant origin were explored. Currently, it is proven activity against JNK compounds such as SR-1347, SP600125, AS601245 and CC-930. Among the plant substances such activity has been shown to curcumin, resveratrol, green tea catechins and epigallocatechin-3-galat.
Larsen A. K. Naringin-sensitive phosphorylation of plectin, a cytoskeletal cross-linking protein, in isolated rat hepatocytes / A. K. Larsen, M. T. Møller, H. Blankson et al. / J Biol Chem. – 2002. – vol. 277, N 38. – P. 34826-34835.
Zhou Y. Y. MAPK/JNK signalling: a potential autophagy regulation pathway / Y. Y. Zhou, Y. Li, W. Q. Jiang et al / Biosci Rep. - 2015. – vol. 35, N 3. - e00199.
Seki E. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches / E. Seki, D. A. Brenner, M. Karin / Gastroenterology. – 2012. – vol. 143, N 2. – P. 307-320.
Soon R. K. Stress signaling in the methionine-choline-deficient model of murine fatty liver disease / R. K. Jr. Soon, J. S. Yan, J. P. Grenert, J. J. Maher / Gastroenterology. – 2010. – Vol. 139(5. – P. 730-739.
Kumar A. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases / A. Kumar, U. K. Singh, S. G. Kini, V. Garg et al. / Future Med Chem. – 2015. –Vol. 7 (15). – P. 2065-2086.
Hirosumi J. A central role for JNK in obesity and insulin resistance / J. Hirosumi, G. Tuncman, L. Chang et al. / Nature. -2002. — vol. 402. — P. 333-336.
Pal M. The roles of c-Jun NH2-terminal kinases (JNKs) in obesity and insulin resistance / M. Pal, M. A. Febbraio, G. I. Lancaster / J Physiol. – 2016. – Vol. 594(2). – P. 267-279.
Zhang J. Y. The role of the c-Jun N-terminal kinase signaling pathway in skin cancer / J. Y. Zhang, M. A. Selim / Am J Cancer Res. -2012. –Vol. 2, N 6. - 691-698.
Zhou Y. Y. MAPK/JNK signalling: a potential autophagy regulation pathway / Y. Y. Zhou, Y. Li, W. Q. Jiang et al. / Biosci Rep. - 2015. – Vol. 35, N 3. - e00199.
Kumar A. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases / A. Kumar, U. K. Singh, S. G. Kini, V. Garg et al. / Future Med Chem. – 2015. – Vol. 7(15). – P. 2065-2086.
Apostol B. L. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice / B. L. Apostol, D. A. Simmons, C. Zuccato, K. Illes et al. / Mol Cell Neurosci. – 2008. – Vol. 39(1). – P. 8-20.
Kristiansen M. Mkp1 is a c-Jun target gene that antagonizes JNK-dependent apoptosis in sympathetic neurons / M. Kristiansen, R. Hughes, P. Patel, T. S. Jacques, A. R. Clark, J .Ham / J Neurosci. – 2010. – Vol. 30(32). – P. 10820-10832.
Brundin P. Improving the survival of grafted dopaminergic neurons: a review over current approaches / P. Brundin, J. Karlsson, M. Emgard еt al. / Cell Transplant. — 2000. — Vol. 9. — P. 179–195.
Zhang G. Y. Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants / G. Y. Zhang, Q. G. Zhang / Expert Opin Investig Drugs. – 2005. – Vol. 14(11). – P. 1373-1383.
Liedhegner E. A. Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease / E. A. Liedhegner, K. M. Steller, J. J. Mieyal / Chem Res Toxicol. – 2011. – Vol. 24(10). – P. 1644-1652.
Guo Z. Z. SP600125 Attenuates Nicotine-Related Aortic Aneurysm Formation by Inhibiting Matrix Metalloproteinase Production and CC Chemokine-Mediated Macrophage Migration / Z. Z. Guo, Q. A. Cao, Z. Z. Li, L. P. Liu / Mediators Inflamm. – 2016. – Vol. 13. – P. 9142-9425.
Park K. H. L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells / K. H. Park, K. S. Shin, T. T. Zhao, H. J. Park, K. E. Lee, M. K. Lee / Neuropharmacology -. 2016. - Vol. 101. – P. 87-97.
Ren H. Porphyromonas gingivalis induces IL-8 and IFN-gamma secretion and apoptosis in human extravillous trophoblast derived HTR8/SVneo cells via activation of ERK1/2 and p38 signaling pathways / H. Ren, Y. Li, H. Jiang, M. Du / Placenta. – 2016. – Vol. 45. – P. 8-15.
Song H. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway / H. Song, D. Y. Hur, K. E. Kim, H. Park et al / Cell Immunol. – 2006. – Vol. 242(1). – P. 39-45.
Gkouveris I. JNK1/2 expression and modulation of STAT3 signaling in oral cancer / I. Gkouveris, N. Nikitakis, M. Karanikou, G. Rassidakis, A. Sklavounou / Oncol Lett. – 2016. – Vol. 12(1). – P. 699-706.
Zhang C, Bi Y, Jin G, Gan H, Yu L. High and fluctuating glucose levels increase the expression and secretion of interleukin‑18 in mouse peritoneal macrophages / C. Zhang, Y. Bi, G. Jin, H. Gan, L. Yu / Mol Med Rep. – 2015. – Vol. 12(2). – P. 2715-2720.
Liu M. 3-MCPD 1-Palmitate Induced Tubular Cell Apoptosis In Vivo via JNK/p53 Pathways / M. Liu, G. Huang, T. T. Wang, X. Sun, L. L Yu / Toxicol Sci. – 2016. – Vol. 151(1). –P. 181-192.
Rodriguez-Ramiro I. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms / I. Rodriguez-Ramiro, D. Vauzour, A. M.Minihane / Proc Nutr Soc. – 2016. – Vol. 75(1). – P. 47-60.
Hsu C. W. Involvement of NF-κB in regulation of Actinobacillus pleuropneumoniae exotoxin ApxI-induced proinflammatory cytokine production in porcine alveolar macrophages / C. W. Hsu, S. C. Li, N. Y. Chang, Z. W. Chen / Vet Microbiol. – 2016. – 195. – P. 128-135.
Bogoyevitch M. A. Inhibitors of c-Jun N-terminal kinases: JuNK no more? / M. A. Bogoyevitch, P. G. / Arthur.Biochim Biophys Acta. – 2008. – Vol. 1784(1). – P .76-93/
Cerbone A/ AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells / A. Cerbone, C. Toaldo, S. Pizzimenti, P. Pettazzoni / PPAR Res. – 2012. – Vol. 12. – P. 269-271/
Li D. Involvement of the JNK/FOXO3a/Bim Pathway in Neuronal Apoptosis after Hypoxic-Ischemic Brain Damage in Neonatal Rats / D. Li, X. Li, J. Wu, J. Li, L. Zhang / PLoS One. – 2015. – Vol. 10(7). – P. e0132998/
Wang L. W. JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain / L. W. Wang, Y. F. Tu, C. C. Huang, C. J. Ho / J Neuroinflammation. – 2012. – Vol. 9. – P. 170-175.
Bubici C. JNK signalling in cancer: in need of new, smarter therapeutic targets / C. Bubici, S. Papa / Br J Pharmacol. – 2014. – Vol. 171(1). – P. 24-37
Atsriku C. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans / C. Atsriku, M. Hoffmann, Y..Ye, G. Kumar, S. Surapaneni /Xenobiotica. – 2015. – Vol. 45(5). – P. 428-41.
Atsriku C. In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism / C. Atsriku, M. Hoffmann, M. Moghaddam, G. Kumar, S. Surapaneni / Xenobiotica. – 2015. – Vol. 45(6). – P. 465-480.
Antoniu S. A. Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis / S. A. Antoniu / Expert Opin. Investig. Drugs. – 2013. – Vol. 22(11). – P. 234-246.
van der Velden J. L. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers / J. L. van der Velden, Y. Ye, J. D. Nolin, S. M. Hoffman / Clin Transl Med. – 2016. – Vol. 5(1). – P. 36-44.
Reich N. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis / N Reich, M Tomcik, P Zerr V.,Lang et al. / Ann Rheum Dis. – 2012. – Vol. 71(5). – P. 737-745.
Moll S. Targeting the epithelial cells in fibrosis: a new concept for an old disease. / S. Moll, L. Chaykovska, M. Meier, D. C. Budd, I. Formentini, S. Pomposiello, M. Prunotto / Drug Discov Today. – 2013. - Vol.10. – P. 2345-2357.
Gan L. T. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent / L. T. Gan, Van D. M. Rooyen, M. Koina, R. S. McCuskey / J Hepatol -. 2014, pii: S0168-8278(14)00523-6.
Ontsouka C. E. In vitro characterization and endocrine regulation of cholesterol and phospholipid transport in the mammary gland / C. E. Ontsouka, X. Huang, E. Aliyev, C. Albrecht / Mol Cell Endocrinol. – 2016. – Vol. 74-85.
Gao B. Whole genome expression profiling and screening for differentially expressed cytokine genes in human bone marrow endothelial cells treated with humoral inhibitors in liver cirrhosis / B. Gao, W. Sun, X. Wang, X. Jia et al. /Int J Mol Med. – 2013. – Vol. 32(5). – P. 1204-1214.
Chin K. Y. The spice for joint inflammation: anti-inflammatory role of curcumin in treating osteoarthritis / K. Y. Chin / Drug Des Devel Ther. – 2016. – Vol. 10. – P. 3029-3042
Qadir M. I. Curcumin: a Polyphenol with Molecular Targets for Cancer Control / M. I. Qadir, S. T. Naqvi, S. A. Muhammad./Asian Pac J Cancer Prev. -2016. - 17(6). –P. 2735-2739.
Tingrong L. Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage / L. Tingrong, L. Chen, S. Haige, L. Tiantian / Inflamm Res. – 2014. – Vol. 35. – P. 1324-1329.
Zhao J. F. Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis / J. F. Zhao, L. C. Ching, Y. C. Huang, C. Y. Chen et al. / Mol Nutr Food Res. – 2012. –Vol. 6(5). – P. 691–701.
Lin T. Y. Curcumin inhibits glutamate release from rat prefrontal nerve endings by affecting vesicle mobilization / T. Y. Lin, C. W. Lu, S. K. Huang, S. J.Wang /Int J Mol Sci. – 2012. – Vol. 13(7). –P. 9097-9109.
Zhong Y. Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-kappaB pathways in rat vascular smooth muscle cells / Y. Zhong, T. Liu, Z.Guo / Inflamm Res. – 2012. – Vol. 61(1). – P.61–67.
Shehzad A. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases / A. Shehzad, T. Ha, F. Subhan, Y. S. Lee /Eur J Nutr. – 2011. – Vol. 50(3). – P. 151–161
Pan Y, Zhang X, Wang Y, Cai L, Ren L, Tang L, Wang J, Zhao Y, Wang Y, Liu Q, Li X, Liang G.Targeting JNK by a new curcumin analog to inhibit NF-kB-mediated expression of cell adhesion molecules attenuates renal macrophage infiltration and injury in diabetic mice. PLoS One. 2013 Nov 18;8(11):e79084
Lv Z. M. The role of the p38 MAPK signaling pathway in high glucose-induced epithelial-mesenchymal transition of cultured human renal tubular epithelial cells / Z. M. Lv, Q. Wang, Q. Wan et al. / PLoS ONE. – 2011. – Vol.6: e22806.
Wang Y. Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation / Y. Wang, Y. Wang, M. Luo, H. Wu et al. /Biochim Biophys Acta. – 2015. – Vol.1. – P. 34-46
Pan Y. Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy / Y. Pan, Y. Wang, Y. Zhao, K, Peng et al. / Diabetes. – 2014. – Vol. 63(10). – P. 3497-3511.
Liu Y. Inhibition of MAPK-mediated ACE expression by compound C66 prevents STZ-induced diabetic nephropathy / Y. Liu, Y. Wang, X. Miao, S. Zhou et al. /J. Cell. Mol. Med. – 2014. - Vol 18, No 2. – P. 231-241
Wang Y. Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression / Y. Wang , Sh. Zhou , W. Sun , K. McClung et al./ American Journal of Physiology – Endocrinology and Metabolism. – 2014. - Vol. 306. – P. E1239-E1247
Wang Y. Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression / Y. Wang, S. Zhou, W. Sun, K. McClung, / Am J Physiol Endocrinol Metab. – 2014. - 306(11). – P. E1239- E1247.
Liu Y. Inhibition of MAPK-mediated ACE expression by compound C66 prevents STZ-induced diabetic nephropathy / Y. Liu, Y. Wang, X. Miao, Sh. Zhou, et al. / J. Cell. Mol. Med. – 2014. - Vol 18. – P. 231-241
Pan Y. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart / Y. Pan, G. Zhu, Y. Wang, L. Cai / J Nutr Biochem. – 2013. – Vol. 24(1). – P. 146-155.
Jain S. The Development of a Critical Care Resident Research Curriculum: A Needs Assessment / S. Jain, K. Menon, D. Piquette, R, Gottesman et al. / Can Respir J. -2016. – Vol. 16. – P.9795-9739.
Ishizawa K. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis / K. Ishizawa, M. Yoshizumi, Y. Kawai, H. Terao / J Pharmacol Sci. – 2011. – Vol. 115(4). – P. 466-470.
Hu Y. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma / Y. Hu, S. Wang, X. Wu, J. Zhang et al. /J Ethnopharmacol. – 2013. – Vol. 149(3). – P. 601-612.
Aggarwal B. B, Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies / B. B. Aggarwal, A. Bhardwaj, R. S. Aggarwal / Anticancer Res. – 2004. – Vol. 24(5A). – P. 2783-2840
Wang H. Protective Effects of Green Tea Polyphenol Against Renal Injury Through ROS-Mediated JNK-MAPK Pathway in Lead Exposed Rats / H. Wang, D. Li, Z. Hu, S. Zhao / Mol Cells. – 2016. – Vol.39(6. –p. 108-113.
Shih L. J. Green tea (-)-epigallocatechin gallate inhibits the growth of human villous trophoblasts via the ERK, p38, AMP-activated protein kinase, and protein kinase B pathways / L. J. Shih, T. F. Chen, C. K. Lin, H. S. Liu /Am J Physiol Cell Physiol . – 2016. – Vol. 311(2). – P. C308-C321.
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).